Prelude Therapeutics Inc.

175 Innovation Boulevard

Wilmington, Delaware 19805

December 15, 2025

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Alan Campbell, Esq.

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Prelude Therapeutics Inc. hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-292048), so that such registration statement may become effective at 4:00 p.m. (Washington, D.C. time) on December 16, 2025 or as soon as practicable thereafter.